Trademark: 87497304
Status Date
Monday, April 5, 2021
Filing Date
Tuesday, June 20, 2017
Published for Opposition
Tuesday, January 2, 2018
Abandoned Date
Monday, April 5, 2021
1 Biochemicals for scientific, laboratory, and research use, namely, proteolytically-activatable, protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells and antigens; diagnostic kits for scientific, laboratory, and research use comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens; immunoglobulin and antigen-binding fragments for drug conjugation and targeted cell binding for laboratory and research use; assays and reagents for use in scientific, laboratory and research purposes; biochemical test kits comprising assays and reagents for scientific, laboratory and research purposes; assay kits comprising assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation and antibody binding for scientific, laboratory and research use
5 Infections, inflammation; infections, inflammation; infections, inflammation; engineered cell therapies for medical purposes, namely, for use in treating cancer, infections, autoimmunity, and inflammation; infections, inflammation; assays and reagents for use in medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; biochemical test kits comprised of assays and reagents for medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; assay kits comprised of assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery for medical, medical diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for use in identifying candidate patient populations for specific therapeutic treatments for medical purposes; therapeutic kits comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens
42 Scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy, oncology and dysregulated proteolytic activity; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research; providing scientific and medical research information and analysis relating to biochemicals, engineered cell therapies and immunotherapy, proteolytic activation, antibody binding, therapeutic treatments, patient recovery, and the identification of candidate patients for specific therapeutic treatments; testing, research, design and development services in the field of biochemicals for scientific and medical research purposes; research, design and development of assays for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery, and for identifying candidate patient populations for specific therapeutic treatments; providing technical support and consultation services relating to antibody selection and use, namely, providing technical scientific research consultation services; online computer services in the nature of providing a search engine for obtaining data, namely, searching, retrieving, and providing information on antibodies and research topics pertaining to antibodies on a global computer network
Color is not claimed as a feature of the mark.
The mark consists of three semi-circles aligned next to each other. The first semi-circle has its vertical opening facing to the right. It is separated by a narrow white space from the second semi-circle, whose vertical opening faces to the left. The third semi-circle's vertical opening faces to the right. The tips of the circular apexes of the second and third semi circles are adjoined to each other.
Apr 5, 2021
Abandonment Notice E-Mailed - No Use Statement Filed
Apr 5, 2021
Abandonment - No Use Statement Filed
Aug 1, 2020
Notice Of Approval Of Extension Request E-Mailed
Jul 31, 2020
Extension 5 Granted
Jul 29, 2020
Extension 5 Filed
Jul 29, 2020
Teas Extension Received
Feb 7, 2020
Notice Of Approval Of Extension Request E-Mailed
Feb 5, 2020
Extension 4 Granted
Feb 5, 2020
Extension 4 Filed
Feb 5, 2020
Teas Extension Received
Jan 30, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 30, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 21, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 21, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 16, 2019
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 16, 2019
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 22, 2019
Notice Of Approval Of Extension Request E-Mailed
Aug 19, 2019
Extension 3 Granted
Aug 19, 2019
Extension 3 Filed
Aug 19, 2019
Teas Extension Received
Feb 19, 2019
Notice Of Approval Of Extension Request E-Mailed
Feb 15, 2019
Extension 2 Granted
Feb 15, 2019
Extension 2 Filed
Feb 15, 2019
Teas Extension Received
Sep 18, 2018
Corrected Noa E-Mailed
Sep 18, 2018
Notice Of Approval Of Extension Request E-Mailed
Sep 17, 2018
Extension 1 Granted
Aug 20, 2018
Extension 1 Filed
Sep 17, 2018
Divisional Processing Complete
Aug 21, 2018
Divisional Request Received
Sep 17, 2018
Case Assigned To Intent To Use Paralegal
Aug 21, 2018
Teas Request To Divide Received
Aug 20, 2018
Teas Extension Received
Feb 27, 2018
Noa E-Mailed - Sou Required From Applicant
Feb 20, 2018
Changes/Corrections After Pub Approval Entered
Feb 16, 2018
Assigned To Petition Staff
Feb 6, 2018
Teas Post Publication Amendment Received
Jan 2, 2018
Official Gazette Publication Confirmation E-Mailed
Jan 2, 2018
Published For Opposition
Dec 13, 2017
Notification Of Notice Of Publication E-Mailed
Nov 26, 2017
Assigned To Lie
Nov 14, 2017
Approved For Pub - Principal Register
Nov 14, 2017
Examiner's Amendment Entered
Nov 14, 2017
Notification Of Examiners Amendment E-Mailed
Nov 14, 2017
Examiners Amendment E-Mailed
Nov 14, 2017
Examiners Amendment -Written
Nov 10, 2017
Previous Allowance Count Withdrawn
Nov 10, 2017
Approved For Pub - Principal Register
Nov 9, 2017
Teas/Email Correspondence Entered
Nov 8, 2017
Correspondence Received In Law Office
Nov 8, 2017
Teas Response To Office Action Received
Jul 24, 2017
Notification Of Examiner's Amendment/Priority Action E-Mailed
Jul 24, 2017
Examiner's Amendment/Priority Action E-Mailed
Jul 24, 2017
Combined Examiner's Amendment/Priority Action Automatic Entry
Jul 24, 2017
Examiners Amendment And/Or Priority Action - Completed
Jul 17, 2017
Assigned To Examiner
Jun 28, 2017
Notice Of Design Search Code E-Mailed
Jun 27, 2017
New Application Office Supplied Data Entered In Tram
Jun 23, 2017
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
